08/08/2016

Bionik, Inc.

Bionik Appoints New Chief Commerical Officer and Expands Commercial Team

August 8, 2016

Bionik Laboratories Appoints Timothy A. McCarthy as Chief Commercialization Officer and Expands Commercial Team

Experienced commercial leader in medical and healthcare technology

Top-producing and results-oriented leader with 20+ years of accomplishments in

developing commercial strategies, building world class global organizations and

growing multimillion-dollar revenues

Additional key appointments for expansion of sales representatives named to launch

commercial strategy

TORONTO and BOSTON, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Bionik Laboratories

Corp. (OTCQX:BNKL) (“Bionik” or the "Company"), a global pioneering robotics company

focused on providing rehabilitation solutions to individuals with neurological disorders,

announced today that it has appointed Timothy A. McCarthy to its Management Team as

Chief Commercialization Officer. Mr. McCarthy is a well-established and successful

commercial leader in medical and healthcare technology. The Company also announced

the addition of Steven L. Brown and Jon C. King to its newly formed global

commercialization team.

Peter Bloch, Chief Executive Officer and Chairman of the Board, stated, “We are delighted

to have Tim join the Bionik team. As a renowned expert in commercialization, and with the

experience he brings, we look forward to driving forward a strong commercial engine, the

number one priority for our growth strategy. This key strategic appointment is another

step for Bionik in positioning the Company as a leader in the robotics medical technology

and device space and propels us closer to bringing more effective rehabilitation solutions

to those with neurological disorders by utilizing innovative technologies and robotics.”

Timothy A. McCarthy joins the Bionik team having recently served as the Chief Executive

Officer of Medical Compression Systems, Inc., a medical device company specializing in

compression therapy to prevent DVT and improve wound healing for joint replacement

patients. He was recruited as the top executive at MCS to lead a commercial stabilization

and turnaround effort in order to prepare the company for an M&A process seeking a

strategic partner. Prior to that, Mr. McCarthy served as the President and CEO of iWALK,

Inc. (now known as BionX Medical Technologies), a venture backed medical robotics

company commercializing the Massachusetts Institute of Technology (“MIT”) invented

BiOM System, the world’s first and only actively powered lower limb bionic prosthesis to

normalize gait. While at iWALK, Inc. Mr. McCarthy was responsible for leading the final

product development and commercial sales strategy that led to the successful

establishment of a long-term market foothold for this new category of healthcare

technology products. In addition, Mr. McCarthy served at Össur Americas as Vice

President of Sales and Marketing, where he was promoted to the top commercial

executive and leader of a sales and marketing restructuring and growth effort, resulting in

above budget attainment each year and 4.5x revenue growth during his nine year tenure.

Mr. McCarthy also held sales leadership roles at the Chattanooga Group, Inc. (now known

as DJO Global). Over the course of his career Mr. McCarthy has proven to be instrumental

in the expansion of public, private and startup healthcare technology and medical device

companies.

“Robotic rehabilitation is an emerging market that represents a vast and growing

opportunity,” commented Mr. McCarthy. “The Bionik team and their range of robotic

rehabilitation systems show incredible promise in the robotic rehabilitation market and

ultimately beyond in the home setting. I am confident that the InMotion Systems and

ARKE have the potential to provide incredible opportunities for effective therapy for a

range of individuals suffering from neurological disorders. I look forward to leading the

Company’s commercial efforts and further advancing Bionik in this potentially fast growing

market to its next stage of growth.”

Mr. McCarthy graduated cum laude from Northeastern University with a Bachelor of

Science in Business Administration and received his Master of Business Administration

from the University of California in Los Angeles.

Bionik also appointed to its commercialization team two key sales executives, Steven L.

Brown and Jon C. King.

Steven L. Brown has over 35 years of significant contributions in key roles with industry

leaders in the field of Rehabilitation and Sports Medicine. Previous to joining the Bionik

team, Mr. Brown served as the National Business Development Manager at Bioness, Inc.

Over the course of his career, Mr. Brown has a diversified and proven management record

in sales, marketing, product management, strategic planning and commercialization.

Jon C. King is a domestic and international business development executive with over 25

years of experience in the field of Physical Medicine and Rehabilitation. Prior to joining the

Bionik team, Mr. King served as the Business Development Manager, Western Region

and Director of International Business Development at Bioness, Inc. Mr. King has a proven

history of increasing sales revenue and maintaining customer relationships on both a

national and international level.

“We are also pleased to welcome Steven Brown and Jon King to our commercialization

team. As we continue to advance Bionik and execute on our business strategy, we believe

these key appointments play an integral part in our ability to do so. We are excited to have

attracted these individuals and continue to focus our efforts on building a premier and

innovative robotics company achieving success globally,” concluded Mr. Bloch.

About Bionik Laboratories

Bionik Laboratories (OTCQX: BNKL), is a global, pioneering robotics company focused on

providing rehabilitation solutions to individuals with neurological disorders. The Company

has a portfolio of products focused on upper and lower extremity rehabilitation for stroke

and paraplegic patients, including three products on the market and three products in

varying stages of development. The InMotion Systems - the InMotion ARM™,

InMotionWrist™, InMotion Hand™ and InMotion Ankle™, are designed to provide

intelligent, patient-adaptive therapy in a manner that has been clinically verified to

maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™,

designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate

through walking. ARKE is expected to be designed to continually adapt to a patient’s ability

and provide real time feedback to the physiotherapist through the use of Bionik’s

proprietary data collection and analytics cloud network through its partnership with IBM.

For more information, please visit www.bioniklabs.com and connect with us on Twitter,

LinkedIn and Facebook.

 Bionik Laboratories, Inc. Investor and Media Contact:

Jenene Thomas

Jenene Thomas Communications, LLC

(908) 996-0239

jenene@jenenethomascommunications.com

Source: Bionik Laboratories Corp.

Exhibitor Data Sheet